iStent® Trabecular Microbypass Stent: An Update

Table 1

Summary of iStent randomized controlled trials.

Authors (year)	TG ()	CG ()	Device	Procedure	TG mean IOP reduction (%)	CG mean IOP reduction (%)	TG med. reduction (%)	CG med. reduction (%)	Follow-up (months)
Samuelson et al. [15] (2011)	117	123	iStent	Phaco. versus Phaco. + 1 iStent	8.2	5.4	86.7	73.3	12
Craven et al. [19] (2012)	117	123	iStent	Phaco. versus Phaco. + 1 iStent	8.1	4.3	80.0	66.7	24
Fernández-Barrientos et al. [26] (2010)	17	16	iStent	Phaco. versus Phaco. + 2 iStents	27.3	16.5	100	41.7	12
Fea [10] (2010)	12	24	iStent	Phaco. versus Phaco. + 1 iStent	17.3	9.2	80.0	31.6	15
Fea et al. [27] (2014)	94	98	iStent inject	2 iStents versus med.	38.4	36.2	N/A	N/A	12

CG, control group; IOP, intraocular pressure; med, medication; Phaco., phacoemulsification; TG, treatment group.
The numerical value listed under “med. reduction” represents the decrease in mean number of IOP lowering medications used postoperatively.